By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Anika Therapeutics 

32 Wiggins Avenue

Bedford  Massachusetts  01730   U.S.A.
Phone: 781-457-9000 Fax: 781-935-4120

Anika Therapeutics is a pioneer in developing therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid (HA), a naturally occurring polymer found throughout the body. HA enhances joint function and coats, protects, cushions and lubricates soft tissues. HA also is present in the skin, where it supports skin structure and elasticity. With more than 20 years of experience in HA technology, Anika is recognized worldwide as a provider of premium HA products that are effective, safe and long-lasting.

Anika manufactures and distributes a diverse portfolio of HA-based products that cover a broad range of therapeutic applications. These products include ORTHOVISC®, ORTHOVISC® mini, and MONOVISC™ used in the treatment of osteoarthritis; HYVISC® used in the treatment of equine osteoarthritis; the ELEVESS™ family of cosmetic dermatology products for facial wrinkles, scar remediation and lip augmentation; AMVISC®, AMVISC® Plus, STAARVISC™ II, and OPTIVISC™ injectable viscoelastic HA products for ophthalmic surgery; INCERT®, an HA-based anti-adhesive for surgical applications; and next-generation products for joint health and aesthetic dermatology based on the Company's proprietary, chemically modified HA.

Key Statistics

Ownership: Public

Web Site: Anika Therapeutics
Symbol: ANIK


Company News
Anika Therapeutics (ANIK) Announces Publication Of Data Demonstrating The Efficacy And Safety Of HYALOFAST In Combination With Stem Cells For The Treatment Of Cartilage Lesions On The Knee 8/8/2017 6:50:08 AM
Anika Therapeutics (ANIK) Announces Appointment Of Joseph Darling As President 7/27/2017 9:00:22 AM
Anika Therapeutics (ANIK) Reports Strong Second Quarter 2017 Financial Results 7/27/2017 7:46:48 AM
Anika Therapeutics (ANIK) Announces Regulatory Approval For MONOVISC In India For The Treatment Of Pain Associated With Osteoarthritis Of All Synovial Joints 7/25/2017 10:12:30 AM
Anika Therapeutics (ANIK) Announces $5 Million Milestone Payment From U.S. Commercial Sales Of MONOVISC 7/18/2017 7:47:56 AM
Anika Therapeutics (ANIK) To Issue Second-Quarter 2017 Financial Results And Business Highlights On Wednesday, July 26 7/13/2017 6:54:59 AM
Anika Therapeutics (ANIK) To Present At The Singular Research Summer Solstice Conference On July 13, 2017 7/7/2017 6:38:55 AM
Anika Therapeutics (ANIK) Announces Data Presentation And Symposium On CINGAL At 2017 EFORT Annual Congress 5/31/2017 6:50:24 AM
Anika Therapeutics (ANIK) Announces First Patient Enrolled In Supplemental Phase III Trial Of CINGAL For The Treatment Of Knee Pain Associated With Osteoarthritis 5/26/2017 6:15:23 AM
Anika Therapeutics (ANIK) Celebrates 25th Anniversary And Inaugurates Newly Expanded And Consolidated Global Manufacturing Facility In Bedford, Massachusetts 5/23/2017 10:07:09 AM